Generic drug: casimersen
Brand name: Amondys 45
What is Amondys 45 (casimersen), and how does it work?
Amondys 45 (casimersen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
What is the dosage for Amondys 45?
Monitoring To Assess Safety
Serum cystatin C, urine dipstick, and
urine protein-to-creatinine ratio (UPCR) should be measured before starting
Amondys 45. Consider measurement of glomerular filtration rate prior to
initiation of Amondys 45. Monitoring for kidney toxicity during treatment is
recommended. Obtain the urine sample prior to infusion of Amondys 45 or at least
48 hours after infusion.
The recommended dosage of
Amondys 45 is 30 milligrams per kilogram administered once weekly as a 35 to 60-minute intravenous infusion via an in-line 0.2 micron filter.
If a dose of
Amondys 45 is missed, it may be administered as soon as possible after the scheduled dose.
What drugs interact with Amondys 45?
No Information Provided
Is Amondys 45 safe to use while pregnant or breastfeeding?
- There are no human or animal data available to assess the use of Amondys
45 during pregnancy.
- There are no human or animal data to assess the effect of Amondys 45 on milk production, the presence of casimersen in milk, or the effects of
Amondys 45 on the breastfed infant.
- The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for
Amondys 45 and any potential adverse effects on the breastfed infant from
Amondys 45 or from the underlying maternal condition.
Medically Reviewed on 4/2/2021
All sections courtesy of the U.S. Food and Drug Administration